EMA: EC Decision: Label Extension / New Indication: Lucentis (ranibizumab)
Novartis Europharm Limited
The European Commission approved a label extension for Lucentis (ranibizumab, Novartis) on May 13, 2026, adding visual impairment due to choroidal neovascularization as a new indication. This represents a Type II variation expanding the existing marketing authorization for the anti-VEGF therapy beyond its current indications for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Novartis gains broader indication coverage in the competitive anti-VEGF ophthalmology market dominated by Eylea (aflibercept) and emerging biosimilars. The approval follows nearly two decades after the original CHMP opinion, reflecting ongoing indication development for the established therapy.
Strategic Signal
This indication expansion positions Lucentis to compete more directly with Eylea across a broader spectrum of retinal vascular diseases, particularly important as aflibercept biosimilars enter European markets. EU ophthalmologists gain additional anti-VEGF flexibility for CNV treatment, though Novartis faces pricing pressure from newer high-dose formulations and biosimilar competition. The timing coincides with Amgen's Pavblu approval in April 2026, intensifying anti-VEGF market competition across multiple retinal indications in Europe.